This incidence increased to 33.2-47% when Nivolumab was combined with the anti-CTLA4 mAb Ipilimumab.20 In our trial, 50.6% of the included patients experienced some degree of pruritus, as assessed by the researcher at baseline. This evidence concerns the gene CTLA4 and Pruritus.